SCHEMBL3365671

SCHEMBL3365671

Nc1ccc(CCc2cccc(Cl)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.68
CYP19A1 P11511 1/20 0.68
MAOB P27338 8/20 0.59
MAOA P21397 4/20 0.59
GFER P55789 1/20 0.56
PNMT P11086 1/20 0.55
BACE1 P56817 1/20 0.54
AOC3 Q16853 1/20 0.53
HTR3E A5X5Y0 1/20 0.53
HTR3B O95264 1/20 0.53
HTR3A P46098 1/20 0.53
HTR3D Q70Z44 1/20 0.53
HTR3C Q8WXA8 1/20 0.53
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
IDO1 P14902 1/20 0.50
AGXT P21549 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15989864 0.85 TAAR1 (0.63) TAAR1MAOBPNMTBACE1AOC3
SCHEMBL12050856 0.85 TAAR1 (0.74) TAAR1PNMTBACE1AOC3HTR3E
SCHEMBL21384185 0.84 TAAR1 (0.57) TAAR1CYP19A1MAOBPNMTHTR3E
SCHEMBL29442800 0.84 TAAR1 (0.57) TAAR1CYP19A1MAOBPNMTHTR3E
SCHEMBL23071686 0.83 TAAR1 (0.65) TAAR1MAOBMAOAPNMTAOC3
SCHEMBL148750 0.81 TAAR1 (1.00) TAAR1MAOBPNMTAOC3HTR3E
SCHEMBL30643998 0.81 TAAR1 (1.00) TAAR1MAOBPNMTAOC3HTR3E
SCHEMBL11333486 0.80 TAAR1 (0.58) TAAR1CYP19A1PNMTBACE1AOC3
SCHEMBL28785069 0.80 TAAR1 (0.57) TAAR1MAOBPNMTAOC3HTR3E
SCHEMBL23071683 0.80 TAAR1 (0.57) TAAR1PNMTBACE1AOC3HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542969-B1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS HOFFMANN LA ROCHE (CH) 2010-03-03 EP disclosed
CN-100503562-C Pyrrolidone derivatives as MAOB inhibitors HOFFMANN LA ROCHE (CH) 2009-06-24 CN disclosed
US-7122562-B2 4-pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-17 US disclosed
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide IDING HANS 2006-06-08 US disclosed
US-7037935-B2 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-05-02 US disclosed
CN-1681777-A Pyrrolidone derivatives as MAOB inhibitors HOFFMANN LA ROCHE (CH) 2005-10-12 CN disclosed
EP-1542969-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-22 EP disclosed
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives HOFFMANN-LA ROCHE INC. 2004-06-03 US disclosed
WO-2004026827-A1 PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106650-A1 4-Pyrrolidino-phenyl-benzyl ether derivatives MAOB, MAOA, COMT TAAR1 798/4885CYP19A1 280/4885MAOB 1/4885
US-20060122235-A1 Amine oxidase inhibitor; use in treating Alzheimer's disease; for example, (RS)-1-[6-(4-fluoro-benzyloxy)-pyridin-3-yl]-5-oxo-pyrrolidine-3-carboxylic acid methylamide MAOA, MAOB, PNPO TAAR1 136/4885CYP19A1 291/4885MAOB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.